Patents by Inventor Emma BLACKHAM

Emma BLACKHAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240010645
    Abstract: Compounds of formula (I): (I) and related aspects.
    Type: Application
    Filed: April 18, 2023
    Publication date: January 11, 2024
    Inventors: Abdul QUDDUS, Andrew NOVAK, David COUSIN, Elli CHATZOPOULOU, Emma BLACKHAM, Geraint JONES, Jennifer THOMAS, Joesph WRIGGLESWORTH, Lorna DUFFY, Louise BIRCH, Pascal GEORGE, Saleh AHMED
  • Publication number: 20230192673
    Abstract: Compounds of formula (I): and related aspects.
    Type: Application
    Filed: November 3, 2022
    Publication date: June 22, 2023
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Emma Blackham, Geraint Jones, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • Patent number: 11655246
    Abstract: Compounds of formula (I): (I) and related aspects.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 23, 2023
    Assignee: STEP PHARMA S.A.S.
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Elli Chatzopoulou, Emma Blackham, Geraint Jones, Jennifer Thomas, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • Publication number: 20230086703
    Abstract: Compounds of formula (I) wherein ring B is selected from the group consisting of Formula (B-a) and Formula (B-bc) as human cytidine triphosphate synthase 1 (CTPS 1) inhibitors for the treatment of proliferative diseases, such as e.g. cancer, such as e.g. leukemia and lymphoma, e.g. inflammatory skin diseases such as psoriasis, or e.g. multiple sclerosis. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. page 129 to page 302; examples; biological examples 1 and 2; tables 1-17). Specific examples are e.g.: N-(4-(5-Chloropyridin-3-yl)phenyl)-2-(2-(cyclopropane-sulfonamido) pyrimidin-4-yl)butanamide (Formula P1) or 1-(2-(Cyclopropanesulfonamido)pyrimidin-4-yl)-N-(4-(6-ethoxypyrazin-2-yl)phenyl)cyclopentanecarboxamide (Formula P2).
    Type: Application
    Filed: June 4, 2020
    Publication date: March 23, 2023
    Applicant: Step Pharma S.A.S.
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Emma Blackham, Ellie Chatzopoulou, Geraint Jones, Jennifer Thomas, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed, Gianna Toschi
  • Publication number: 20230020663
    Abstract: The invention provides a compound of formula (I) and processes for the manufacture of such compounds, related intermediates, compositions comprising such compounds and the use of such compounds as cytidine triphosphate synthase 1 inhibitors, particularly in the treatment or prophylaxis of disorders associated with cell proliferation.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 19, 2023
    Applicant: Step Pharma S.A.S.
    Inventors: Andrew Novak, Abdul Quddus, David Cousin, Joseph Wrigglesworth, Emma Blackham, Geraint Jones, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • Publication number: 20230002352
    Abstract: The invention provides a compound of formula (I): formula (I) and the use of such compounds as cytidine triphosphate synthase 1 inhibitors, particularly in the treatment or prophylaxis of disorders associated with cell proliferation.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 5, 2023
    Applicant: Step Pharma S.A.S.
    Inventors: Andrew Novak, Abdul Quddus, David Cousin, Joseph Wrigglesworth, Emma Blackham, Geraint Jones, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • Publication number: 20220324837
    Abstract: Compounds of formula (I) as human cytidine triphosphate synthase 1 (CTPS1) inhibitors for the treatment of prolifera-tive diseases, such as e.g. cancer, such as e.g. leukemia and lymphoma, e.g. inflammatory skin diseases such as psoriasis, or e.g. multiple sclerosis. The present description discloses the synthesis and characterisa-tion of exemplary compounds as well as pharmacological data thereof (e.g. pages 64 to 80; examples; biological examples 1 and 2; e.g. compounds P140, P231 to P263; tables 1 to 10). Specific examples are e.g.: N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonami-N do) pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (Formula (II)), or 1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)cyclohexane-1-carboxamide (Formula (III)).
    Type: Application
    Filed: June 4, 2020
    Publication date: October 13, 2022
    Applicant: Step Pharma S.A.S.
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Emma Blackham, Geraint Jones, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • Publication number: 20210387965
    Abstract: Compounds of formula (I), and related aspects.
    Type: Application
    Filed: October 23, 2019
    Publication date: December 16, 2021
    Applicant: Step Pharma S.A.S.
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Emma Blackham, Geraint Jones, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • Publication number: 20210024507
    Abstract: Compounds of formula (I): and related aspects.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 28, 2021
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Emma Blackham, Geraint Jones, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • Publication number: 20210002269
    Abstract: Compounds of formula (I): (I) and related aspects.
    Type: Application
    Filed: November 11, 2018
    Publication date: January 7, 2021
    Inventors: Abdul QUDDUS, Andrew Novak, David COUSIN, Elli CHATZOPOULOU, Emma BLACKHAM, Geraint JONES, Jennifer Thomas, Joesph WRIGGLESWORTH, Lorna DUFFY, Louise BIRCH, Pascal GEORGE, Saleh AHMED